We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Generic and Biosimilar Medicinal Products in the European Union

30 April 2007

Chemistry Today
The recent revisions of the Community Codes on Medicinal Products introduced a number of changes to the procedure for granting marketing authorisation for generic medicinal products, both human and veterinary. Among the changes are the introduction of a process for authorisation of “biosimilar” products. The term "biosimilar" is perceived in some corners as an acknowledgement of the fact that it is not possible to produce a generic version of a biotechnology product. This article examines how the authorisation process for biosimilars has operated in practice in its first year of application.

The team

Loading data